Richard J. D'ANdrea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard J. D'ANdrea has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Saumya E. Samaraweera
Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia
71 shared publications - Brooks A. Benard
Stanford University
66 shared publications - Daniel Thomas
School of Medicine, College of Health, Adelaide University, Adelaide, Australia
66 shared publications - Angel F. Lopez
Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia
65 shared publications - Paul G. Ekert
Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
65 shared publications - Andy G. X. Zeng
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
64 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 821-836
Fancl -mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing
Fanconi anemia (FA) is a rare genetic disorder causing the progressive loss of hematopoietic stem cells (HSCs) and bone marrow failure. Most cases result from deficient monoubiquitination of FANCD2 by the FA core complex. However, given that additional functions for the complex have been proposed, it remains unclear whether loss of FANCD2 monoubiquitination is the sole cause of all FA phenotypes. Here, we generated a murine allele (FanclTATΔ) that mimics an allele from a patient with FA. This 3-bp deletion removes a catalytic cysteine in the E3 RING ligase domain of the FANCL subunit. Biochemical assays show that the mutant FA core complex retains structural integrity but lacks FANCD2 monoubiquitination activity. Homozygous FanclTATΔ/TATΔ mice phenocopy classical human FA features, including infertility, craniofacial anomalies, DNA damage hypersensitivity, and progressive HSC loss with age. Correcting the mutation using CRISPR-Cas9 or prime editing technology restores FANCD2 monoubiquitination and normal DNA damage resistance in myeloid cells. Collectively, our mouse model demonstrates that loss of RING E3 ubiquitin ligase activity of the FA core complex explains developmental defects and hematopoietic failure in FA and provides a new animal model for testing potentially therapeutic gene editing.
- 2 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 821-836
Open AccessFancl -mutant mice reveal central role of monoubiquitination in Fanconi anemia and a model for therapeutic gene editing
Fanconi anemia (FA) is a rare genetic disorder causing the progressive loss of hematopoietic stem cells (HSCs) and bone marrow failure. Most cases result from deficient monoubiquitination of FANCD2 by the FA core complex. However, given that additional functions for the complex have been proposed, it remains unclear whether loss of FANCD2 monoubiquitination is the sole cause of all FA phenotypes. Here, we generated a murine allele (FanclTATΔ) that mimics an allele from a patient with FA. This 3-bp deletion removes a catalytic cysteine in the E3 RING ligase domain of the FANCL subunit. Biochemical assays show that the mutant FA core complex retains structural integrity but lacks FANCD2 monoubiquitination activity. Homozygous FanclTATΔ/TATΔ mice phenocopy classical human FA features, including infertility, craniofacial anomalies, DNA damage hypersensitivity, and progressive HSC loss with age. Correcting the mutation using CRISPR-Cas9 or prime editing technology restores FANCD2 monoubiquitination and normal DNA damage resistance in myeloid cells. Collectively, our mouse model demonstrates that loss of RING E3 ubiquitin ligase activity of the FA core complex explains developmental defects and hematopoietic failure in FA and provides a new animal model for testing potentially therapeutic gene editing.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα P248 at the IL-3R assembly interface is critical for cell differentiation.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα P248 at the IL-3R assembly interface is critical for cell differentiation.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Summary of the key interactions in the IL-3R ternary complex in the IL-3R ternary complex crystal structure.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Summary of the key interactions in the IL-3R ternary complex in the IL-3R ternary complex crystal structure.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
The IL-3R dodecamer activates STAT1 to induce cell differentiation.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
The IL-3R dodecamer activates STAT1 to induce cell differentiation.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Key interactions between distinct residues in the IL-3R ternary complex crystal structure.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Key interactions between distinct residues in the IL-3R ternary complex crystal structure.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Enrichment of the IL-3R hexamer versus dodecamer gene signature in primitive normal and leukemic stem cells.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Enrichment of the IL-3R hexamer versus dodecamer gene signature in primitive normal and leukemic stem cells.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Data collection and refinement statistics for the IL-3R ternary complex crystal structure.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Data collection and refinement statistics for the IL-3R ternary complex crystal structure.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα/βc transcript and protein expression ratio in AML patient samples.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα/βc transcript and protein expression ratio in AML patient samples.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Increasing IL3Rα/βc ratios lead to hexameric receptor assembly and augmented quiescence.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Increasing IL3Rα/βc ratios lead to hexameric receptor assembly and augmented quiescence.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Increasing IL3Rα/βc ratios and enforced hexamer signaling lead to reduced differentiation in in vivo engraftments.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Increasing IL3Rα/βc ratios and enforced hexamer signaling lead to reduced differentiation in in vivo engraftments.